[Neurogastroenterology And Motility] Human-derived intestinal organoids were grown from pediatric disorders of gut-brain interaction and non-IBD colon biopsies. Colonoids were treated with 250 nM linaclotide and assayed for cGMP to develop a model of guanylin cyclase C activity.
[Frontiers in Oncology] The authors present a comprehensive review on the construction methods and potential applications of lung cancer organoids in both preclinical and clinical research.
[Nature Medicine] Scientists showed that there was a specific multiplicative interaction between female sex and PNPLA3 p.I148M in determining fatty liver disease in at-risk individuals (steatosis and fibrosis, and advanced fibrosis/hepatocellular carcinoma) and in the general population.
[Signal Transduction and Targeted Therapy] In this randomized, double-blind, placebo-controlled study, investigators assessed the efficacy and safety of FOLFOX4 with all-trans-retinoic acid as a palliative treatment for HCC patients with extrahepatic metastasis, compared to FOLFOX4 with a placebo.
[JHEP Reports] Researchers conducted a cohort study with data from Swedish university hospitals. Patients with nonalcoholic fatty liver disease (NAFLD) without cirrhosis were diagnosed through biopsy or radiology, and had fibrosis estimated.
[Expert Review of Clinical Immunology] Scientists explore the role of Tregs in the immune system, delve into their contribution to cancer and tumor progression, and highlight therapeutic strategies targeting Tregs, along with innovative delivery systems.
[Cell Research] Researchers unveiled a mechanism for V-domain Ig suppressor of T cell activation (VISTA) regulation in T cells and highlights targeting tripartite motif containing 25 (TRIM25)–VISTA as a potential strategy to enhance tumor immunotherapy.
[Leukemia] The authors conducted integrated genome-wide CRISPR-Cas9 loss-of-function screens using CD30-specific CAR-engineered NK cells, alongside a complementary PD-L1 regulator screen, and uncovered a critical role for interleukin-1 receptor signaling in modulating CAR therapy efficacy in both ALK⁺ and ALK⁻ anaplastic large cell lymphoma.